| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC2255 |
| Trial ID | NCT04171843 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | PBCAR269A |
| Co-treatment | nirogacestat |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma |
| Year | 2020 |
| Country | United States |
| Company sponsor | Precision BioSciences, Inc. |
| Other ID(s) | PBCAR269A-01 |
| Cohort 1 | |||||||||||
|
|||||||||||